Drug Res (Stuttg) 2019; 69(05): 284-290
DOI: 10.1055/a-0672-0707
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Lysimachia Capillipes Inhibit Adipogenesis via Angiogenesis Inhibition

Xiumin Li
1   The Engineering Technological Center of Mushroom Industry, Minnan Normal University, Zhangzhou, Fujian, China
,
Yu Xue
1   The Engineering Technological Center of Mushroom Industry, Minnan Normal University, Zhangzhou, Fujian, China
,
Liang Pang
2   The College of Physical Education, Minnan Normal University, Zhangzhou, Fujian, China
,
Zhaoshui ShangGuan
3   Central Laboratory, the First Affiliated Hospital of Xiamen University, Xiamen China
,
Yutian Pan
1   The Engineering Technological Center of Mushroom Industry, Minnan Normal University, Zhangzhou, Fujian, China
› Author Affiliations
Further Information

Publication History

received 07 March 2018

accepted 06 August 2018

Publication Date:
07 September 2018 (online)

Abstract

Obesity is a common and increasingly prevalent human condition due to unhealthy diet and less-exercise lifestyle. Development of obesity is associated with substantial modulation of adipose tissue structure. The expansion of adipose tissue is linked to the development of its vasculature, and modulation of angiogenesis may have the potential to impair adipose tissue development. In this study, we used obesity model of zebrafish fed by egg yolk to investigate the effect of Lysimachia capillipes on the obesity. The results showed that Lysimachia capillipes inhibited angiogenesis of adipose tissue in transgenic zebrafish Tg (Fli 1: EGFP), which was similar to surppressing effect of TNP-470, which was accompanied by decreased Oil Red O staining of the zebrafish. The treatment of Lysimachia capillipes reduced expression of MTP significantly, but modestly reduced expression of Ppar g, FABP10a, and CD36 level through ISH, which was accordant with the results by PCR analysis. The study proved that Lysimachia capillipes might possess novel therapeutic properties for prevention and treatment of obesity.

 
  • References

  • 1 Tingaud-Sequeira A, Ouadah N, Babin PJ. Zebrafish obesogenic test: A tool for screening molecules that target adiposity. J Lipid Res 2011; 52: 1765-1772
  • 2 Haque MR, Ansari HS. Anti-obesity effect of Arq Zeera and Its main components thymol and cuminaldehyde in high fat diet induced obese rats. Drug Res 2018; Apr 10 DOI: 10.1055/a-0590-1956.. [Epub ahead of print]
  • 3 Nakagami H. The mechanism of white and brown adipocyte differentiation. Diabetes & Metabolism Journal 2013; 37: 85-90
  • 4 Sanchez-Gurmaches J, Guertin DA. Adipocyte lineages: Tracing back the origins of fat. Biochim Biophys Acta 2014; 1842: 340-351
  • 5 Kolonin MG, Saha PK, Chan L. et al. Reversal of obesity by targeted ablation of adipose tissue. Nat Med 2004; 10: 625-632
  • 6 De Falco S. Antiangiogenesis therapy: An update after the first decade. The Korean Journal of Internal Medicine 2014; 29: 1-11
  • 7 Ledoux S, Quequiner I, Msika S. et al. Angiogenesis associated with visceral and subcutaneous adipose tissue in severe human obesity. Diabetes. 2008; 57: 3247-3257
  • 8 Rupnick MA, Panigrahy D, Zhang CY. et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A 2002; 99: 10730-10735
  • 9 Cao Y. Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nature reviews. Drug discovery. 2010; 9: 107-115
  • 10 Daquinag AC, Zhang Y, Kolonin MG. Vascular targeting of adipose tissue as an anti-obesity approach. Trends in pharmacological sciences 2011; 32: 300-307
  • 11 Fei ZH, Wu K, Chen YL. et al. Capilliposide Isolated from Lysimachia capillipes Hemsl. Induces ROS Generation, Cell Cycle Arrest, and Apoptosis in Human Nonsmall Cell Lung Cancer Cell Lines. Evid Based Complement Alternat Med 2014; 2014: 497456
  • 12 Liang B, Zhang L, Tian J. et al. Isolation and characterization of two new saponins from Lysimachia capillipes. Carbohydrate research. 2006; 341: 2444-2448
  • 13 Xie C, Xu LZ, Luo XZ. et al. Flavonol glycosides from Lysimachia capillipes. Journal of Asian Natural Products Research 2002; 4: 17-23
  • 14 White HM, Acton AJ, Considine RV. The angiogenic inhibitor TNP-470 decreases caloric intake and weight gain in high-fat fed mice. Obesity (Silver Spring) 2012; 20: 2003-2009
  • 15 Hines J, Ju R, Dutschman GE. et al. Reversal of TNP-470-induced endothelial cell growth arrest by guanine and guanine nucleosides. J Pharmacol Exp Ther 2010; 334: 729-738
  • 16 Meguro S, Hasumura T, Hase T. Body fat accumulation in zebrafish is induced by a diet rich in fat and reduced by supplementation with green tea extract. PLoS One. 2015; 10: e0120142
  • 17 Flynn 3rd EJ, Trent CM, Rawls JF. Ontogeny and nutritional control of adipogenesis in zebrafish (Danio rerio). J Lipid Res 2009; 50: 1641-1652
  • 18 Misra M. Obesity pharmacotherapy: Current perspectives and future directions. Current Cardiology Reviews 2013; 9: 33-54
  • 19 Hosogai N, Fukuhara A, Oshima K. et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes. 2007; 56: 901-911
  • 20 Rutkowski JM, Davis KE, Scherer PE. Mechanisms of obesity and related pathologies: The macro- and microcirculation of adipose tissue. The FEBS Journal 2009; 276: 5738-5746
  • 21 Flier JS. Obesity wars: Molecular progress confronts an expanding epidemic. Cell. 2004; 116: 337-350
  • 22 Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest 2011; 121: 2094-2101
  • 23 Polvani S, Tarocchi M, Tempesti S. et al. Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer. World Journal of Gastroenterology 2016; 22: 2441-2459
  • 24 Chawla A. Control of macrophage activation and function by PPARs. Circ Res. 2010; 106: 1559-1569
  • 25 Monsalve FA, Pyarasani RD, Delgando-Lopez F. et al. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators Inflamm. 2013; 2013: 549627
  • 26 Larsen TM, Toubro S, Astrup A. PPARgamma agonists in the treatment of type II diabetes: Is increased fatness commensurate with long-term efficacy?. Int J Obes Relat Metab Disord 2003; 27: 147-161
  • 27 Den Broeder MJ, Kopylova VA, Kamminga LM. et al. Zebrafish as a model to study the role of peroxisome proliferating-activated receptors in adipogenesis and obesity. PPAR research 2015; 2015: 358029
  • 28 Schulman IG. Nuclear receptors as drug targets for metabolic disease. Advanced Drug Delivery Reviews 2010; 62: 1307-1315
  • 29 Zhang X, Young HA. PPAR and immune system – what do we know?. International Immunopharmacology. 2002; 2: 1029-1044
  • 30 Majdalawieh A, Ro HS. PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1. Nuclear Receptor Signaling 2010; 8: e004
  • 31 Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998; 391: 82-86